Why Is Biohaven Stock Soaring Wednesday?
Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.
Read original at benzingaStocks · News reference
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 3:38 PM
- Checked
- Aug 12, 2026, 3:38 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Biohaven shares are trading higher after the company announced that the U.S. District Court for the District of Delaware ruled in its favor in the case against Avilar Therapeutics. Biohaven announced a collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to the company's Kv7 ion channel platform.
Read original at benzinga8-K filing — Biohaven Ltd. (BHVN)
Filed: 2026-08-26 AccNo: 0001935979-26-000072 Size: 890 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarWhy JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares rise 3.6% in pre-market trading.
Read original at benzinga